The American Academy of Ophthalmology 2014 Annual Meeting will be held in Chicago, IL from October 18–21, 2014. We have assembled a pre-meeting listing of highlights based on presentation titles and abstracts that were released.

Top-line and retrospective presentations are expected for ESBA1008 and Fovista for wet AMD. With long-term studies of wet AMD outcomes with Lucentis and Eylea treatment behind us, the struggle for anti-VEGF market share has moved to diabetic macular edema (DME), an indication in which Eylea and Ozurdex have recently received approval.

For our disclosures, please read the BioMedTracker Research Standards.